<DOC>
	<DOCNO>NCT01298323</DOCNO>
	<brief_summary>The purpose study evaluate effect patient outreach program proportion time patient MTC experience moderate severe AEs first 12 month treatment vandetanib</brief_summary>
	<brief_title>Study Determine Contacting Patients With MTC More Frequently Results Earlier Detection Treatment Signs Symptoms AEs Thus Decrease Percentage Time Patients Experience AEs During First 12 Months Vandetanib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Female male age 18 year Previously confirm histological diagnosis unresectable , locally advanced metastatic hereditary sporadic MTC . Documentation must provide patient 's medical chart WHO ECOG Performance status 02 Negative pregnancy test ( urine serum ) female patient childbearing potential Unstable brain metastasis spinal cord compression require treatment , unless treat least 4 week first dose stable without steroid treatment 10 day Major surgery within 4 week randomization The last dose prior chemotherapy receive less 3 week prior randomization Radiation therapy complete prior first dose vandetanib Significant cardiac event , superior vena cava syndrome , NYHA classification heart disease ≥2 , within 12 week randomization , presence cardiac disease opinion Investigator increase risk ventricular arrhythmia Creatinine clearance &lt; 30 ml/min ( calculate CockcroftGault formula ) , Patients moderate renal impairment , define creatinine clearance ≥30 &lt; 50 ml/min , must start vandetanib reduce dose 200 mg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Medullary Thyroid Cancer</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Vandetanib</keyword>
	<keyword>Patient Outreach</keyword>
</DOC>